WuXi Biologics (Cayman) Inc.
(Incorporated in the Cayman Islands with limited liability)

Press Releases       

2021-August-23	WuXi Biologics 2021 Interim Results, Revenue Increases by 126.7% Y-o-Y to RMB4,406.8 Million, Gross Profit Grows by 191.7% Y-o-Y to RMB2,296.8 Million, Adjusted Net Profit Attributable to Owners of the Company Increases by 163.0% Y-o-Y to RMB1,768.7 Million, Gross and Net Profit Margins Reach 52.1% and 42.7%, Respectively, Diluted EPS Reaches RMB0.42 with 133.3% Growth Y-o-Y (in PDF)
2021-March-23	2020 Results Record High Despite a Challenging Year, Revenue Increased by 40.9% Y-o-Y to RMB5,612 Million, Gross Profit Rose by 52.7% Y-o-Y to RMB2,533 Million, Net Profit Grew by 67.5% Y-o-Y to RMB1,693 Million, Record-high Gross Margin of 45.1% and Net Profit Margin of 30.2%, Milestone Revenue Surged by 71.7% to US$95 Million, Total Backlog up 122.0% to US$11,324 Million (in PDF)
2022	2022 Press Releases
2020	2020 Press Releases
2019	2019 Press Releases
2018	2018 Press Releases
2017	2017 Press Releases